EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Progestins and breast cancer hallmarks: The role of the ERK1/2 and JNK pathways in estrogen receptor positive breast cancer cells

Renate Louw-du Toit, Mishkah Simons, Donita Africander

The Journal of Steroid Biochemistry and Molecular Biology · 2024

DOI: 10.1016/j.jsbmb.2023.106440 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Steroid Biochemistry and Molecular Biology, 2024. Verfasst von Renate Louw-du Toit und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry, University of Stellenbosch, Private Bag X1, Matieland 7602, South Africa. Electronic address: renate@sun.ac.za. Hauptthemen laut MEDLINE: Progestins, Breast Neoplasms. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 93 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Medical Research Council of South Africa, Medical Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Progestins used in hormonal contraceptives and menopausal hormone therapy (MHT) have been linked to increased breast cancer risk. Whether the association holds for all progestins is unclear and the underlying mechanisms remain poorly understood. We directly compared the effects of four progestins (medroxyprogesterone acetate (MPA), norethisterone acetate (NET-A), levonorgestrel (LNG) and drospirenone (DRSP)) to each other and the natural progestogen progesterone (P4) on selected cancer hallmarks. To provide mechanistic insight into these effects, we assessed the role of the progesterone receptor (PR), and the extracellular signal-related kinase (ERK1/2) and c-Jun N terminal (JNK) signaling pathways. We showed that the increased proliferation of the luminal T47D breast cancer cell line by P4 and all progestins, albeit to different extents, was inhibited by PR knockdown and inhibition of both the ERK1/2 and JNK pathways. While knockdown of the PR also blocked the upregulation of MKI67 and CCND1 mRNA expression by selected progestogens, only a role for the ERK1/2 pathway could be established in these effects. Similarly, only a role for the ERK1/2 pathway could be confirmed for progestogen-induced colony formation, whereas both the ERK1/2 and JNK pathways were required for cell migration in response to the three older progestins implicated in the etiology of breast cancer, MPA, NET-A and LNG. Together our results show that all the progestins elicit their effects on cell proliferation via a mechanism requiring the PR, ERK1/2 and JNK pathways. While the ERK1/2 and JNK pathways are also required for increased cell migration by the older progestins, only a role for the ERK1/2 pathway could be established in their effects on colony formation. Notably, the cytoplasmic PR was not needed for activation of the ERK1/2 pathway by the progestogens. Given that DRSP showed significantly lower proliferation than MPA and NET-A, and that it had no effect on breast cancer cell migration and colony formation, hormonal formulations containing the newer generation progestin DRSP may provide a better benefit/risk profile towards breast cancer than those containing the older generation progestins.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ProgestinsBreast NeoplasmsHumansFemaleMAP Kinase Signaling SystemProgesteroneMedroxyprogesterone AcetateLevonorgestrelReceptors, ProgesteroneReceptors, Estrogen

Stichwörter der Autor:innen

Breast cancerERK1/2JNKMenopausal hormone therapyProgesterone receptorProgestins

Substanzen

ProgestinsProgesteroneMedroxyprogesterone AcetateLevonorgestrelReceptors, ProgesteroneReceptors, Estrogen

Autor:innen und Institutionen

  • Department of Biochemistry, University of Stellenbosch, Private Bag X1, Matieland 7602, South Africa. Electronic address: renate@sun.ac.za.
  • Department of Biochemistry, University of Stellenbosch, Private Bag X1, Matieland 7602, South Africa. Electronic address: mishkah@sun.ac.za.
  • Department of Biochemistry, University of Stellenbosch, Private Bag X1, Matieland 7602, South Africa. Electronic address: drho@sun.ac.za.

Förderung

  • Medical Research Council of South Africa
  • Medical Research Council

Zitieren

APA

Louw-du Toit, R., Simons, M., & Africander, D. (2024). Progestins and breast cancer hallmarks: The role of the ERK1/2 and JNK pathways in estrogen receptor positive breast cancer cells. The Journal of Steroid Biochemistry and Molecular Biology. https://doi.org/10.1016/j.jsbmb.2023.106440

Vancouver

Louw-du Toit R, Simons M, Africander D. Progestins and breast cancer hallmarks: The role of the ERK1/2 and JNK pathways in estrogen receptor positive breast cancer cells. The Journal of Steroid Biochemistry and Molecular Biology. 2024. doi:10.1016/j.jsbmb.2023.106440

BibTeX
@article{LouwduToit2024,
  author = {Louw-du Toit, Renate and Simons, Mishkah and Africander, Donita},
  title = {Progestins and breast cancer hallmarks: The role of the ERK1/2 and JNK pathways in estrogen receptor positive breast cancer cells},
  journal = {The Journal of Steroid Biochemistry and Molecular Biology},
  year = {2024},
  doi = {10.1016/j.jsbmb.2023.106440}
}
Kostenlos starten →